United Therapeutics Corporation (UTHR)
| Market Cap | 23.55B +16.0% |
| Revenue (ttm) | 3.15B +2.5% |
| Net Income | 1.31B +5.5% |
| EPS | 27.95 +9.0% |
| Shares Out | 42.89M |
| PE Ratio | 19.65 |
| Forward PE | 20.74 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 577,860 |
| Open | 528.92 |
| Previous Close | 532.78 |
| Day's Range | 528.92 - 551.15 |
| 52-Week Range | 409.07 - 609.35 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 651.86 (+18.7%) |
| Est. Earnings | Oct 28, 2026 |
About UTHR
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price target is $651.86, which is an increase of 18.70% from the latest price.
News
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court ...
Liquidia slumps after US court rules for United Therapeutics in patent fight
Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics , dealing a major blow to the treatment's commer...
United Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Fourteen new therapies are being launched for pulmonary and fibrotic diseases, with a focus on disruptive innovation, robust financial stewardship, and a transformative organ manufacturing program targeting commercial launch by 2030. AI-driven drug development and a high-efficiency culture underpin rapid growth and industry leadership.
United Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A major strategic shift is underway, expanding from orphan pulmonary hypertension to large pulmonary fibrosis markets, with strong clinical data supporting new launches and ambitious revenue targets. Multiple product formulations and sales force expansions are planned, while regulatory confidence remains high for upcoming approvals.
United Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A major clinical and commercial transformation is underway, with best-in-class pulmonary fibrosis data, a rapidly expanding addressable market, and 14 product launches planned through 2029. Launch readiness, polypharmacy strategies, and a $500 million stock buyback highlight strong momentum and confidence in reaching $50–$100 billion in revenue by the early 2030s.
United Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Fourteen new products are set for rapid launch, targeting $50–100 billion in annual pharma revenue and addressing a million-patient market. Key innovations include once-daily and coughless inhalers, with strong IP protection and major investments in manufacturing and xenotransplantation.
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the rema...
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the suppleme...
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fir...
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four p...
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug...
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (trepr...
United Therapeutics Earnings Call Transcript: Q2 2026
Exceptional clinical results and major regulatory filings set the stage for multi-billion dollar opportunities in PAH and IPF. Q2 revenue was flat sequentially at $783 million, with competitive pressures on TYVASO but strong underlying patient metrics and expanded sales force supporting a positive outlook for the second half of 2026.
United Therapeutics Quarterly report: Q2 2026
United Therapeutics has published its Q2 2026 quarterly earnings report on August 5, 2026.
United Therapeutics Slides: Q2 2026
United Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
United Therapeutics Earnings release: Q2 2026
United Therapeutics released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
United Therapeutics Corporation Reports Second Quarter 2026 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full res...
United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Victor...
United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a pr...
United Therapeutics Corporation Acquires Thymmune Therapeutics
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately h...
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administra...
United Therapeutics Transcript: AGM 2026
The virtual annual meeting marked the company's 30th anniversary, with all director nominees elected and all shareholder proposals approved. No questions were raised by shareholders, and voting results will be reported in a forthcoming SEC filing.
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...